tetano
Editor, Senior Moderator
Source: DGNews | Posted 8 hours ago
Protective Levels of Antibodies Against H1N1 Persist 1 Year After Immunisation With AS03B-Adjuvanted Vaccine
: Presented at ESPID
Tags:
Immunisation
Influenza
Influenza A (H1N1)
Read/Add Comments | Email This | Print This
By Jenny Powers
THE HAGUE, Netherlands -- June 13, 2011 -- Children who received 2 doses of AS03[]B[]-adjuvanted vaccine had antibody levels that could be protective against the same H1N1 strain in a second flu season, according to study results presented today at the 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID).
A booster with seasonal trivalent influenza vaccine (TIV) at 1 year was well tolerated and highly immunogenic, added investigator Woolf T. Walker, MD, Wellcome Trust Clinical Research Facility, University of Southampton, and Southampton National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit, Southampton University Hospitals National Health Service Trust, Southampton, United Kingdom.
Additionally, it is safe to administer TIV in the season following pandemic vaccine administration.
Dr. Walker presented these results from a study that determined the persistence of antibodies at 13 months post vaccination in children aged 6 months to 12 years who received either 2 doses of AS03[]B[]-adjuvanted or nonadjuvanted monovalent pandemic H1N1 influenza vaccine in a previous study, and, in this trial, evaluated the immunogenicity and reactogenicity of a dose of a seasonal TIV in these vaccinated children.
At 13 months following the last dose in the initial trial, blood samples from 323 children were taken and the levels of antibody against the 2009 pandemic H1N1 influenza virus were determined. Of this group, 302 children were given a single dose of TIV and immunogenicity was assessed by microneutralisation (MN) at day 21.
The 13-month assessment showed a decrease in antibody levels in both vaccination groups; however, a significant percentage of children who received AS03B-adjuvanted vaccine had MN titres of 1:40 or greater compared with children who were given the nonadjuvanted vaccine.
Furthermore, titres of persistent antibody were higher in children aged 3 years and under than in those aged 3 to 12 years at the time of receiving the first dose; the percentage of children who had persistent antibody levels who were under age 3 at first immunisation with AS03B-adjuvanted vaccine was 100% (95% confidence interval [CI], 94.1%-100%) and 32.4% (95% CI, 21.5%-44.8%) for children who received nonadjuvanted vaccine (P <.001).
In the groups that received immunisation at an older age, 96.9% (95% CI, 91.3%-99.4%) of children receiving AS03B-adjuvanted vaccine and 65.9% (95% CI, 55.3%-75.5%) of children who were given nonadjuvanted vaccine had persistent antibody (P <.001).
At 21 days post administration of TIV, all children had MN titres of 1:40 or greater. The groups that had initially received AS03B-adjuvanted vaccine had higher absolute haemagglutination inhibition titre levels than did those in the nonadjuvanted vaccine groups.
More severe local reactions were seen in the children younger 5 years of age in the AS03B-adjuvanted groups than in the nonadjuvanted groups. Redness greater than 50 mm and any severe local reaction were seen in 40.8% versus 24.2% of children younger than 5 years of age, and in 14.1% versus 1.5% of older children in the AS03B-adjuvanted and nonadjuvanted groups, respectively (P <.05).
This study was funded by the NIHR Health Management Programme.
[Presentation title: Persistence of Antibody Against H1N1 and Response to Trivalent Influenza Vaccine 13 Months After 2 Doses of Monovalent Pandemic Vaccines. Abstract 1365]
http://www.docguide.com/protective-...3b-adjuvanted-vaccine?tsid=25&anchor=comments
Protective Levels of Antibodies Against H1N1 Persist 1 Year After Immunisation With AS03B-Adjuvanted Vaccine
: Presented at ESPID
Tags:
Immunisation
Influenza
Influenza A (H1N1)
Read/Add Comments | Email This | Print This
By Jenny Powers
THE HAGUE, Netherlands -- June 13, 2011 -- Children who received 2 doses of AS03[]B[]-adjuvanted vaccine had antibody levels that could be protective against the same H1N1 strain in a second flu season, according to study results presented today at the 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID).
A booster with seasonal trivalent influenza vaccine (TIV) at 1 year was well tolerated and highly immunogenic, added investigator Woolf T. Walker, MD, Wellcome Trust Clinical Research Facility, University of Southampton, and Southampton National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit, Southampton University Hospitals National Health Service Trust, Southampton, United Kingdom.
Additionally, it is safe to administer TIV in the season following pandemic vaccine administration.
Dr. Walker presented these results from a study that determined the persistence of antibodies at 13 months post vaccination in children aged 6 months to 12 years who received either 2 doses of AS03[]B[]-adjuvanted or nonadjuvanted monovalent pandemic H1N1 influenza vaccine in a previous study, and, in this trial, evaluated the immunogenicity and reactogenicity of a dose of a seasonal TIV in these vaccinated children.
At 13 months following the last dose in the initial trial, blood samples from 323 children were taken and the levels of antibody against the 2009 pandemic H1N1 influenza virus were determined. Of this group, 302 children were given a single dose of TIV and immunogenicity was assessed by microneutralisation (MN) at day 21.
The 13-month assessment showed a decrease in antibody levels in both vaccination groups; however, a significant percentage of children who received AS03B-adjuvanted vaccine had MN titres of 1:40 or greater compared with children who were given the nonadjuvanted vaccine.
Furthermore, titres of persistent antibody were higher in children aged 3 years and under than in those aged 3 to 12 years at the time of receiving the first dose; the percentage of children who had persistent antibody levels who were under age 3 at first immunisation with AS03B-adjuvanted vaccine was 100% (95% confidence interval [CI], 94.1%-100%) and 32.4% (95% CI, 21.5%-44.8%) for children who received nonadjuvanted vaccine (P <.001).
In the groups that received immunisation at an older age, 96.9% (95% CI, 91.3%-99.4%) of children receiving AS03B-adjuvanted vaccine and 65.9% (95% CI, 55.3%-75.5%) of children who were given nonadjuvanted vaccine had persistent antibody (P <.001).
At 21 days post administration of TIV, all children had MN titres of 1:40 or greater. The groups that had initially received AS03B-adjuvanted vaccine had higher absolute haemagglutination inhibition titre levels than did those in the nonadjuvanted vaccine groups.
More severe local reactions were seen in the children younger 5 years of age in the AS03B-adjuvanted groups than in the nonadjuvanted groups. Redness greater than 50 mm and any severe local reaction were seen in 40.8% versus 24.2% of children younger than 5 years of age, and in 14.1% versus 1.5% of older children in the AS03B-adjuvanted and nonadjuvanted groups, respectively (P <.05).
This study was funded by the NIHR Health Management Programme.
[Presentation title: Persistence of Antibody Against H1N1 and Response to Trivalent Influenza Vaccine 13 Months After 2 Doses of Monovalent Pandemic Vaccines. Abstract 1365]
http://www.docguide.com/protective-...3b-adjuvanted-vaccine?tsid=25&anchor=comments